Clinical Trial Update: Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating oral ibrexnafungerp (SCY-078) versus placebo for acute vulvovaginal candidiasis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candida Vulvovaginitis
• Vulvovaginal Candidiasis

Drugs mentioned

• Ibrexafungerp (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Candida Vulvovaginitis | Phase 3 | Status: COMPLETED | Results posted: 2021-09-08